Literature DB >> 18348314

Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.

Virginia M B Lorena1, Alinne F A Verçosa, Raquel C A Machado, Lucas Moitinho-Silva, Maria G A Cavalcanti, Edimilson D Silva, Antonio G P Ferreira, Rodrigo Correa-Oliveira, Valéria R A Pereira, Yara M Gomes.   

Abstract

We propose to analyze the relation between the cellular immune response of Chagas' disease patients after in vitro stimulation of peripheral blood mononuclear cells (PBMC) with recombinant antigens cytoplasmatic repetitive antigen (CRA) or flagellar repetitive antigen (FRA) of T. cruzi and the chronic clinical forms of disease. Cells were stimulated using phytohemagglutinin, CRA, FRA, or a soluble antigen of Epimastigota (Ag-Epi) for 24 hr, 72 hr, or 6 days. The proliferation of cells was evaluated after 6 days of culture by quantification of incorporated 3H-thymidine. Cytokines were measured in the supernatants obtained after 24 hr (tumor necrosis factor [TNF]-alpha and interleukin [IL]-4), 72 hr (IL-10), and 6 days (interferon [IFN]-gamma) using enzyme-linked immunosorbent assay (ELISA). Cells of the Chagas patients stimulated with the recombinant antigens exhibited higher proliferation responses compared with that of non-Chagas (NC) individuals. However, when proliferation was compared between patients with the cardiac form (CF) or indeterminate form (IF), it was not possible to establish a difference in the response. So far as the cytokines secreted in the culture supernatants after stimulation in vitro with T. cruzi antigens were concerned, the results showed that CRA, as well as Epi-Ag, were able to stimulate the production of TNF-alpha and IFN-gamma in Chagas patients as compared with NC individuals. However, the cytokine levels after stimulation with the T. cruzi antigens were not different between the patients with CF and IF. CRA was capable of inducing a T helper type 1 (Th1) immune response, with elevated production of TNF-alpha and IFN-gamma in Chagas patients that are carriers of CF and IF clinical forms. (Copyright ) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18348314      PMCID: PMC6649253          DOI: 10.1002/jcla.20209

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  49 in total

1.  Cellular immune responses of chagasic patients to antigens derived from different Trypanosoma cruzi strains and clones.

Authors:  M J Morato; Z Brener; J R Cançado; R M Nunes; E Chiari; G Gazzinelli
Journal:  Am J Trop Med Hyg       Date:  1986-05       Impact factor: 2.345

2.  Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection.

Authors:  P Pinge-Filho; C E Tadokoro; I A Abrahamsohn
Journal:  Cell Immunol       Date:  1999-04-10       Impact factor: 4.868

3.  Comparative analysis of cell phenotypes in different severe clinical forms of Chagas' disease.

Authors:  Glenda M Cardoso; M J F Morato; J A S Gomes; M O C Rocha; I P Bonfim; S Williams-Blangero; J L VandeBerg; M R Reis; E F L Magalhães; R Correa-Oliveira
Journal:  Front Biosci       Date:  2006-01-01

4.  Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease.

Authors:  Susana A Laucella; Miriam Postan; Diana Martin; Bolyn Hubby Fralish; Maria C Albareda; Maria G Alvarez; Bruno Lococo; Gustavo Barbieri; Rodolfo J Viotti; Rick L Tarleton
Journal:  J Infect Dis       Date:  2004-02-17       Impact factor: 5.226

Review 5.  Cytokine production profile of heart-infiltrating T cells in Chagas' disease cardiomyopathy.

Authors:  E Cunha-Neto; L V Rizzo; F Albuquerque; L Abel; L Guilherme; E Bocchi; F Bacal; D Carrara; B Ianni; C Mady; J Kalil
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

6.  Immunodetection of antibodies in sera from symptomatic and asymptomatic Chilean Chagas' disease patients with Trypanosoma cruzi recombinant antigens.

Authors:  M Lorca; A Gonzalez; C Veloso; V Reyes; U Vergara
Journal:  Am J Trop Med Hyg       Date:  1992-01       Impact factor: 2.345

7.  Control of Chagas disease.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2002

8.  Differential regulation of lymphoproliferative responses to Trypanosoma cruzi antigen in patients with the cardiac or indeterminate form of Chagas disease.

Authors:  Sílvia de Barros-Mazon; Maria E Guariento; Cleide Aparecida da Silva; Robert L Coffman; Ises A Abrahamsohn
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

9.  Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection.

Authors:  M S Cetron; F P Basilio; A P Moraes; A Q Sousa; J N Paes; S J Kahn; M H Wener; W C Van Voorhis
Journal:  Am J Trop Med Hyg       Date:  1993-09       Impact factor: 2.345

10.  Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection.

Authors:  J S Silva; P J Morrissey; K H Grabstein; K M Mohler; D Anderson; S G Reed
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  6 in total

1.  Increase in the expression of CD4 + CD25+ lymphocytic T cells in the indeterminate clinical form of human Chagas disease after stimulation with recombinant antigens of Trypanosoma cruzi.

Authors:  Suellen Carvalho de Moura Braz; Adriene Siqueira de Melo; Maria da Glória Aureliano de Melo Cavalcanti; Sílvia Marinho Martins; Wilson de Oliveira; Edimilson Domingos da Silva; Antonio Gomes Pinto Ferreira; Virginia Maria Barros de Lorena; Yara de Miranda Gomes
Journal:  J Clin Immunol       Date:  2014-09-10       Impact factor: 8.317

2.  Association of NFκB and related-cytokines with the viral load and development of antibodies against HHV-8 in people living with HIV/AIDS.

Authors:  Juliana Prado Gonçales; Thaísa Regina Rocha Lopes; Virginia Maria Barros de Lorena; Melayne Rocha Aciole; José Valter Joaquim Silva Júnior; Tania Regina Tozetto-Mendoza; Paulo Henrique Braz-Silva; Maria Rosangela Cunha Duarte Coêlho
Journal:  Med Microbiol Immunol       Date:  2019-10-04       Impact factor: 3.402

3.  Cytokine production but lack of proliferation in peripheral blood mononuclear cells from chronic Chagas' disease cardiomyopathy patients in response to T. cruzi ribosomal P proteins.

Authors:  Silvia A Longhi; Augusto Atienza; Graciela Perez Prados; Alcinette Buying; Virginia Balouz; Carlos A Buscaglia; Radleigh Santos; Laura M Tasso; Ricardo Bonato; Pablo Chiale; Clemencia Pinilla; Valeria A Judkowski; Karina A Gómez
Journal:  PLoS Negl Trop Dis       Date:  2014-06-05

4.  Methodological approach to the ex vivo expansion and detection of T. cruzi-specific T cells from chronic Chagas disease patients.

Authors:  Gonzalo R Acevedo; Silvia A Longhi; Alcinette Bunying; Nazila Sabri; Augusto Atienza; María P Zago; Radleigh Santos; Valeria A Judkowski; Clemencia Pinilla; Karina A Gómez
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

5.  Immunoprophylactic Potential of a New Recombinant Leishmania infantum Antigen for Canine Visceral Leishmaniasis: An In Vitro Finding.

Authors:  Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Victor Vaitkevicius-Antão; Wagner José Tenório Dos Santos; Franklin Barbalho Magalhães; Danielle Maria Nascimento Moura; Eiji Kevin Nakasone Nakasone; Virgínia Maria Barros de Lorena; Milena de Paiva-Cavalcanti
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

6.  Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico.

Authors:  Liliana E Villanueva-Lizama; Julio V Cruz-Chan; Amarú Del C Aguilar-Cetina; Luis F Herrera-Sanchez; Jose M Rodriguez-Perez; Miguel E Rosado-Vallado; Maria J Ramirez-Sierra; Jaime Ortega-Lopez; Kathryn Jones; Peter Hotez; Maria Elena Bottazzi; Eric Dumonteil
Journal:  PLoS Negl Trop Dis       Date:  2018-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.